tumor burden

Summary

Summary: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.

Top Publications

  1. pmc Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel
    Diana M Cittelly
    Departments of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Mol Cancer Ther 11:2556-65. 2012
  2. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
  3. ncbi Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
    Shengri Liao
    Department of Radiology, University of Chicago, Chicago, IL 60637, USA
    Eur J Nucl Med Mol Imaging 39:27-38. 2012
  4. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
  5. ncbi Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer
    Yukinori Matsuo
    Department of Radiation Oncology and Image Applied Therapy, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Int J Radiat Oncol Biol Phys 79:1104-11. 2011
  6. ncbi Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study
    Achilles J Fakiris
    Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 75:677-82. 2009
  7. ncbi Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
    Premal H Thaker
    Department of Gynecologic Oncology, University of Texas U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, Texas 77030, USA
    Nat Med 12:939-44. 2006
  8. pmc DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
    Stefanie Galban
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 7:e35857. 2012
  9. ncbi Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden
    Jenette Creaney
    National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
    Clin Cancer Res 17:1181-9. 2011
  10. pmc Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography
    Muthuveni Ezhil
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, USA
    Radiat Oncol 4:4. 2009

Detail Information

Publications355 found, 100 shown here

  1. pmc Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel
    Diana M Cittelly
    Departments of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Mol Cancer Ther 11:2556-65. 2012
    A therapeutic intervention that could decrease tumor burden and increase sensitivity to chemotherapy would have a significant impact on the high morbidity rate associated with ovarian cancer...
  2. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..that circulating MDSC levels correlate with clinical cancer stage, CTX-based chemotherapy, and metastatic tumor burden. Whole blood was collected from 106 newly diagnosed solid tumor patients (stages I-IV)...
  3. ncbi Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
    Shengri Liao
    Department of Radiology, University of Chicago, Chicago, IL 60637, USA
    Eur J Nucl Med Mol Imaging 39:27-38. 2012
    The objective of this study was to assess the prognostic value of metabolic tumor burden on 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) positron emission tomography (PET)/CT measured with metabolic tumor volume (MTV) and total lesion ..
  4. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
    ....
  5. ncbi Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer
    Yukinori Matsuo
    Department of Radiation Oncology and Image Applied Therapy, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Int J Radiat Oncol Biol Phys 79:1104-11. 2011
    ..To investigate the factors that influence clinical outcomes after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC)...
  6. ncbi Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study
    Achilles J Fakiris
    Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 75:677-82. 2009
    ..The 50-month results of a prospective Phase II trial of stereotactic body radiation therapy (SBRT) in medically inoperable patients are reported...
  7. ncbi Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
    Premal H Thaker
    Department of Gynecologic Oncology, University of Texas U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, Texas 77030, USA
    Nat Med 12:939-44. 2006
    ..Here, we show that chronic behavioral stress results in higher levels of tissue catecholamines, greater tumor burden and more invasive growth of ovarian carcinoma cells in an orthotopic mouse model...
  8. pmc DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
    Stefanie Galban
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 7:e35857. 2012
    ..DW-MRI provided early changes to radiosensitization treatment warranting evaluation of this imaging biomarker in clinical trials...
  9. ncbi Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden
    Jenette Creaney
    National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
    Clin Cancer Res 17:1181-9. 2011
    ..To examine the clinical utility of soluble mesothelin in patients with malignant pleural mesothelioma...
  10. pmc Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography
    Muthuveni Ezhil
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, USA
    Radiat Oncol 4:4. 2009
    ..To determine the optimal approach to delineating patient-specific internal gross target volumes (IGTV) from four-dimensional (4-D) computed tomography (CT) image data sets used in the planning of radiation treatment for lung cancers...
  11. ncbi YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
    ..Further extensive investigation of YM155 in many types of cancer, including HRPC, seems to be worthwhile to develop this novel therapeutic approach...
  12. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
    ..chloride (LiCl) treatment activated Wnt signaling in osteoblasts, inhibited myeloma bone disease, and decreased tumor burden in bone, but increased tumor growth when 5TGM1 cells were inoculated subcutaneously...
  13. pmc The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
    Peter Boross
    Department of Immunology, Lundlaan 6, 3584 EA Utrecht, The Netherlands
    Haematologica 96:1822-30. 2011
    ..However, their specific contributions to the in vivo mechanism of action of CD20 immunotherapy have not been well defined...
  14. ncbi Significance of primary tumor volume and T-stage on prognosis in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
    Chuanben Chen
    Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, 91 Maluding, Fuma Road, Fuzhou 350014, Fujian, People s Republic of China
    Jpn J Clin Oncol 41:537-42. 2011
    ..The aim of this study was to evaluate the effect of the primary tumor volume on prognosis in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy...
  15. pmc NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma
    Anita Gaurnier-Hausser
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6010, USA
    Clin Cancer Res 17:4661-71. 2011
    ..Here, we set out to determine whether dogs with spontaneous DLBCL have comparative aberrant constitutive NF-κB activity and to determine the therapeutic relevance of NF-κB inhibition in dogs with relapsed, resistant DLBCL...
  16. ncbi Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance
    Stefan Lang
    Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Austria
    Radiother Oncol 107:26-31. 2013
    ..To investigate dosimetric uncertainties of MRI-based cervix cancer brachytherapy, when applying two HDR fractions for each applicator insertion and their clinical relevance...
  17. pmc The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss
    Jitesh Pratap
    Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Mol Cancer Ther 9:3210-20. 2010
    ..Vorinostat treatment reduces tumor growth in bone and accompanying osteolytic disease as a result of decreased tumor burden in bone. However, vorinostat can promote osteopenia throughout the skeleton independent of tumor cell activity.
  18. ncbi Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers
    Youguang Zhao
    Department of Urology, General Hospital of Chengdu Military Area Command of Chinese PLA, Chengdu, 610083 Sichuan Province, People s Republic of China
    Mol Cell Biochem 353:93-9. 2011
    ..The 5/35 fiber-modified adenoviral vector-based gene transfer shows an improved efficacy against bladder cancers. The application of this novel gene therapy vector may benefit the patients in clinical bladder cancer treatment...
  19. ncbi The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy
    Seza A Gulec
    Florida International University College of Medicine, Jackson North Medical Center, 100 NW 170th Street Suite 410, North Miami Beach, FL 33169, USA
    Eur J Nucl Med Mol Imaging 38:1289-95. 2011
    ....
  20. ncbi Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice
    Chih Min Yang
    Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan
    Mol Nutr Food Res 55:606-12. 2011
    ..In this study, we evaluated the efficacy of lycopene against the growth of prostate cancer in vivo...
  21. pmc Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth
    Mark Katakowski
    Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Cancer Lett 335:201-4. 2013
    ..Intra-tumor injection of exosomes derived from miR-146-expressing MSCs significantly reduced glioma xenograft growth in a rat model of primary brain tumor...
  22. ncbi Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo
    Sarita Saraswati
    Genome Research Laboratory, Delhi Institute of Pharmaceutical Sciences and Research, Pushp Vihar Sec 3, MB Road, New Delhi 110 017, India
    Cancer Lett 332:83-93. 2013
    ..Taken together, our study suggests that brucine potently suppresses angiogenesis by targeting VEGFR2 activation and may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies...
  23. pmc Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma
    Erin M Burns
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Carcinogenesis 34:370-7. 2013
    ..if topical treatment of previously damaged skin with an anti-inflammatory COX-2 inhibitor would decrease tumor burden and if it would be equally effective in the sexes...
  24. ncbi Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI
    Tord Hompland
    Group of Radiation Biology and Tumor Physiology, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    Cancer Res 72:4899-908. 2012
    ..00001). Together, these findings establish that Gd-DTPA-based DCE-MRI can noninvasively visualize tumor IFP, and they reveal the potential for v(0) determined by this method to serve as a novel general biomarker of tumor aggressiveness...
  25. ncbi Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging
    Hyun Su Kim
    Department of Radiology and Center for Imaging Science, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    J Magn Reson Imaging 37:187-93. 2013
    ....
  26. ncbi Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis
    Cun Wang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China
    Int J Biochem Cell Biol 44:2308-20. 2012
    ..In addition, sCLU also plays an important role in the regulation of TGF-β1-smad3 signaling. These findings suggest that sCLU may promote HCC metastasis via the induction of EMT process and may be a candidate target for HCC therapy...
  27. ncbi Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo
    Mohammad Akbar Hossain
    Division of Pharmacy, College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan 609 735, Republic of Korea
    Int J Oncol 40:1636-42. 2012
    ..Therefore, the combination of ASA and DOX could be used as a novel combination regimen which provides a strong anticancer synergy in the treatment of hepatocellular carcinoma...
  28. pmc Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy
    Johannes C A Dimopoulos
    Metropolitan Hospital, Athens, Greece
    Radiother Oncol 103:113-22. 2012
    ....
  29. pmc Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes
    Karen P Chu
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 83:1521-7. 2012
    ..We hypothesized that increases in MTV over time would correlate with tumor growth and biology, and would predict outcome. We sought to examine tumor growth over time in serial pretreatment PET-CT scans...
  30. ncbi Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications
    Mathieu Hatt
    Institut National de la Santé et de la Recherche Médicale U650 Brest, France
    Int J Radiat Oncol Biol Phys 77:301-8. 2010
    ..In addition, the definition of variable uptake regions within the tumor itself may facilitate dose painting for dosimetry optimization...
  31. ncbi Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy
    Zhongxing X Liao
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 76:775-81. 2010
    ..This retrospective study compares disease outcomes and toxicity in patients treated with concomitant chemotherapy and either 4DCT/IMRT or 3DCRT...
  32. ncbi Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance?
    Allen M Chen
    Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, California 95817, USA
    Int J Radiat Oncol Biol Phys 81:943-9. 2011
    ....
  33. pmc Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model
    Kai Wen Huang
    Hepatitis Research Center, Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan
    Proc Natl Acad Sci U S A 107:14769-74. 2010
    ..Our study implies that in the future, the combination therapy may prove effective for the treatment of patients with advanced HCC...
  34. ncbi RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    Robert E Miller
    Department of Hematology Oncology Research, Amgen Washington, Seattle, Washington 98119 3105, USA
    Mol Cancer Ther 7:2160-9. 2008
    ..directly prevents osteolysis via blockade of osteoclastogenesis and indirectly reduces progression of skeletal tumor burden by reducing local growth factor and calcium concentrations...
  35. ncbi SmartArc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy
    Stefania Clemente
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 80:1248-55. 2011
    ..To investigate the roles of volumetric modulated arc therapy with SmartArc (VMAT-S), intensity-modulated radiation therapy (IMRT), and helical tomotherapy (HT) for oropharyngeal cancer using a simultaneous integrated boost (SIB) approach...
  36. ncbi Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo
    Zhao Hong Wang
    Department of Hepatobiliary Pancreatic Surgery, the Second Affiliated Hospital of Wenzhou Medical College, No 109, West Xue yuan Road, Wenzhou 325027, P R China
    Int J Oncol 39:1123-31. 2011
    ..This study suggests that emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-κB expression, thus inhibiting the expression of XIAP...
  37. ncbi Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases
    Alexander Chi
    Department of Radiation Oncology, The University of Arizona, Tucson, AZ 85724 5081, USA
    Int J Radiat Oncol Biol Phys 81:856-62. 2011
    ..To investigate the ability of helical tomotherapy (HT) to spare critical organs immediately adjacent to the tumor target in stereotactic body radiation therapy (SBRT) for centrally located lung lesions...
  38. ncbi Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway
    Domenico Ribatti
    Dipartimento di Anatomia umana e Istologia, Universita degli Studi di Bari, Italy
    Cancer Treat Rev 37:344-52. 2011
    ..It would appear that the future of angiogenic inhibitors lies in the intelligent combination of multiple targeted agents with other angiogenic inhibitors, as well as more conventional therapies to maximise therapeutic effect...
  39. ncbi Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients
    Mojgan Taremi
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 82:967-73. 2012
    ..To present the results of stereotactic body radiotherapy (SBRT) for medically inoperable patients with Stage I non-small-cell lung cancer (NSCLC) and contrast outcomes in patients with and without a pathologic diagnosis...
  40. pmc Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden
    L Connelly
    Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232 6838, USA
    Oncogene 30:1402-12. 2011
    ..We observed an increase in tumor latency and a decrease in final tumor burden in DNMP mice compared with PyVT controls...
  41. pmc Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer
    Cynthia S Snyder
    Moores UCSD Cancer Center, University of California, La Jolla, CA, USA
    BMC Cancer 9:106. 2009
    ..goal, we performed whole-body fluorescence imaging and ultrasound imaging to evaluate and to compare these noninvasive imaging modalities for assessing tumor burden and tumor progression in an orthotopic mouse model of pancreatic cancer.
  42. ncbi Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Clinical Oncology at the Sir Y K Pao Centre for Cancer, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
    Int J Radiat Oncol Biol Phys 66:714-20. 2006
    ..This study tested the hypotheses that pEBV DNA reflects tumor burden and metabolic activity by evaluating its relationship with tumor volume and 18F-fluorodeoxyglucose (18F-FDG) ..
  43. ncbi Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection
    Mohit Agarwal
    Department of Internal Medicine, William Beaumont Hospital, 3601 W 13 Mile Rd, Royal Oak, MI 48073 6769, United States
    Lung Cancer 68:398-402. 2010
    ..Purpose of the present study was the identification of independent clinico-pathological predictors of their survival...
  44. ncbi Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm
    Atsuya Takeda
    Department of Radiology, Ofuna Chuo Hospital, Kamakura, Japan Department of Radiology, Tokyo Metropolitan Hiroo General Hospital, Tokyo, Japan
    Int J Radiat Oncol Biol Phys 73:442-8. 2009
    ..To retrospectively analyze the clinical outcomes of stereotactic body radiotherapy (SBRT) for patients with Stages 1A and 1B non-small-cell lung cancer...
  45. ncbi Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma
    Kui Hin Liau
    Hepatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1948-55. 2005
    ..Surgical resection for large (> 10 cm) hepatocellular carcinoma (HCC) is believed by many to be ineffective. The objective of the current study was to review the outcome of partial hepatectomy in patients with large HCC...
  46. ncbi Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis
    Valerie Panet-Raymond
    Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, QC, Canada
    Int J Radiat Oncol Biol Phys 73:473-8. 2009
    ..In an attempt to improve results, we have begun a program of accelerated hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concomitant and adjuvant temozolomide (TMZ)...
  47. ncbi Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
    ..EASL) guidelines recommended that assessment of tumor response should incorporate the reduction in viable tumor burden. The current report provides an assessment of the agreement/concordance between both RECIST and the EASL ..
  48. ncbi (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT
    Gerard G Hanna
    Centre for Cancer Research and Cell Biology, Queen s University of Belfast, Belfast, Northern Ireland, United Kingdom
    Int J Radiat Oncol Biol Phys 77:24-30. 2010
    ..In previously PET-CT staged patients with NSCLC, we assessed the effect of using an additional planning PET-CT scan for gross tumor volume (GTV) definition...
  49. ncbi Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study
    Shreerang A Bhide
    Institute of Cancer Research, London, United Kingdom
    Int J Radiat Oncol Biol Phys 76:1360-8. 2010
    ....
  50. pmc Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway
    Srinivas Reddy Boreddy
    Department of Biomedical Sciences and Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, USA
    Clin Cancer Res 17:1784-95. 2011
    ..In this study we hypothesized the involvement of PI3K/AKT/FOXO pathway in BITC-induced apoptosis...
  51. ncbi Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
    Rinat Yerushalmi
    Division of Medical Oncology, BC Cancer Agency, Cancer Agency, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Breast Cancer Res Treat 132:131-42. 2012
    ..Results may have relevance to the development of therapeutics targeting IGF-1R...
  52. ncbi Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage
    Satoru Oshino
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Japan
    Endocr J 53:125-32. 2006
    ..These results will lead to more effective selection of patients for preoperative octreotide treatment...
  53. pmc Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer
    Trang H La
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 74:1335-41. 2009
    ....
  54. ncbi Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden
    Zain Paroo
    The University of Texas Southwestern Medical Center at Dallas, 75390 9058, USA
    Mol Imaging 3:117-24. 2004
    ..shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.
  55. pmc Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes
    Gisela Weskamp
    Arthritis and Tissue Degeneration Program, Caspary Research Building, Room 426, Hospital for Special Surgery, 535 E 70th St, New York, NY 10021, USA
    Circ Res 106:932-40. 2010
    ..These findings raised interesting questions about the role of ADAM17 in angiogenesis and neovascularization in vivo...
  56. ncbi Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix
    Daniel Zwahlen
    Radiation Medicine Program, Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 74:1157-64. 2009
    ..To determine the feasibility and benefits of optimized magnetic resonance imaging (MRI)-guided brachytherapy (BT) for cancer of the cervix...
  57. ncbi Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice
    Jiann Ming Wu
    Department of Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan
    Cancer Lett 287:187-95. 2010
    ..These data suggest that tetrandrine induced significant apoptosis of cultured and subcutaneous CT-26 cells. Tetrandrine-induced apoptosis might be at least partially related to activation of the p38 MAPK signaling pathway...
  58. pmc Role of tissue factor in cancer
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4834-8. 2009
    ..Nevertheless, additional studies are needed to determine if this strategy can be successfully translated to the treatment of cancer patients...
  59. ncbi Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era
    Alexander V Louie
    Department of Radiation Oncology, London Regional Cancer Program, London, Ont, Canada
    Radiother Oncol 95:166-71. 2010
    ..To investigate inter-observer and intra-observer target volume delineation (TVD) error in 4D-CT imaging of thoracic tumours...
  60. ncbi Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Gherardo Mazziotti
    Department of Medical and Surgical Sciences, University of Brescia, c o Endocrinology Service, Montichiari Hospital, Via Ciotti 154, 25018, Montichiari, Italy
    Pituitary 13:60-7. 2010
    ..This finding suggests that this drug may have a role in the primary treatment of acromegaly...
  61. ncbi Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy
    Frank J Lagerwaard
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 75:253-9. 2009
    ..We used RA to plan and deliver whole-brain radiotherapy (WBRT) with a simultaneous integrated boost in patients with multiple brain metastases...
  62. ncbi IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer
    Asa Andersson
    Department of Medicine, University of California Los Angeles Lung Cancer Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 182:6951-8. 2009
    ..IL-7 decreased tumor burden with concomitant increases in the frequency of CD4 and CD8 T lymphocyte subsets, T cell activation markers ..
  63. pmc PI3Kα inhibitors that inhibit metastasis
    Oleg Schmidt-Kittler
    The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Oncotarget 1:339-48. 2010
    ..These data support the idea that PI3Kα plays an important role in the metastatic process and suggest a more informed strategy for selecting drugs worthy of further development for clinical application...
  64. ncbi A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
    Andrea Schaefer
    Department of Nuclear Medicine, Saarland University Medical Center, 66421, Homburg, Germany
    Eur J Nucl Med Mol Imaging 35:1989-99. 2008
    ..An easily applicable algorithm for the FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer was developed by phantom measurements and validated in patient data...
  65. ncbi Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis
    Ling Zhi Liu
    Department of Pathology, Lab of Reproductive Medicine, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu, China
    Cancer Res 68:8183-8. 2008
    ..This study helps to understand the role and molecular mechanism of p70S6K1 in regulating angiogenesis and tumor growth, and the role of endothelial p70S6K1/HIF-1 signaling in the regulation of tumor microenvironment and angiogenesis...
  66. pmc Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
    Victor F Mautner
    Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany
    Neuro Oncol 10:593-8. 2008
    ..Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop...
  67. ncbi Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy
    Anna Strongin
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 82:1823-30. 2012
    ..The present study attempted to add to the existing data on tumor volume as a prognostic factor among patients undergoing chemoradiotherapy...
  68. pmc Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e35711. 2012
    ..The aim of this study was to establish an international cohort of patients with quantified whole-body internal tumor burden and to correlate tumor burden with clinical features of disease.
  69. ncbi Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes
    Benjamin H Lok
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1851-7. 2012
    ..To analyze the effect of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) on treatment outcomes in patients treated with definitive intensity-modulated radiation therapy (IMRT) for oropharyngeal cancer (OPC)...
  70. ncbi Epidemiology and natural history of vestibular schwannomas
    Sven Eric Stangerup
    Department of Oto Rhino Laryngology, Head and Neck Surgery, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Otolaryngol Clin North Am 45:257-68, vii. 2012
    ..A treatment strategy based on the natural history of tumor growth and hearing also is discussed...
  71. ncbi Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy
    Petra Georg
    Department of Radiotherapy, Medical University of Vienna, Vienna, Austria
    Int J Radiat Oncol Biol Phys 79:356-62. 2011
    ..To evaluate the predictive value of dose-volume histogram (DVH) parameters for late side effects of the rectum, sigmoid colon, and bladder in image-guided brachytherapy for cervix cancer patients...
  72. ncbi 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts
    Satoshi Takeuchi
    Department of Medical Oncology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060 8638, Japan
    Oncol Rep 26:725-30. 2011
    ..01). These results suggest that 18F-FLT-PET/CT can be a useful predictor to determine the response to molecular targeted drugs such as cetuximab at an earlier time point than the change of tumor size...
  73. ncbi Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma
    Wei Wang
    Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College, Taizhou, Zhejiang, China
    Int J Radiat Oncol Biol Phys 77:617-21. 2010
    ..To quantify the target and normal structures on dose distributing variations during intensity-modulated radiotherapy (IMRT) and to assess the value of replanning for nasopharyngeal carcinoma (NPC) patients...
  74. ncbi A case-case study of mobile phone use and acoustic neuroma risk in Japan
    Yasuto Sato
    Department of Public Health, School of Medicine, Tokyo Women s Medical University, Shinjuku ku, Tokyo, Japan
    Bioelectromagnetics 32:85-93. 2011
    ..However, we could not conclude that the increased risk was entirely explicable by these biases, leaving open the possibility that mobile phone use increased the risk of acoustic neuroma...
  75. ncbi Primary tumor volume calculation as a predictive factor of prognosis in nasopharyngeal carcinoma
    Ching Chih Lee
    Department of Otolaryngology, Buddhist Tzu Chi Dalin General Hospital, Dalin, Chiayi, Taiwan
    Acta Otolaryngol 128:93-7. 2008
    ..Besides the current AJCC staging system, measurement of PTV may be needed to predict prognosis of NPC and adjust treatment strategy...
  76. ncbi CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice
    Jon Hansen
    Infectious Disease Immunology, Statens Serum Institut, Building 81 306, Copenhagen S, Denmark
    Cancer Immunol Immunother 61:893-903. 2012
    ....
  77. pmc Quantitative analysis of tumor burden in mouse lung via MRI
    Vanessa K Tidwell
    Department of Electrical and Systems Engineering, Washington University in St Louis, St Louis, Missouri 63130, USA
    Magn Reson Med 67:572-9. 2012
    ..Respiratory-gated MRI is a key tool for quantitatively measuring lung-tumor burden and monitoring the time-course progression of individual tumors in mouse models of primary and metastatic lung ..
  78. ncbi Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy
    Seung Uon Shin
    Department of Medicine, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, 1475 N W 12th Avenue D8 4 Miami, FL 33136, USA
    Mol Cancer Ther 10:603-14. 2011
    ....
  79. ncbi Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer
    Percy Lee
    Department of Radiation Oncology, Stanford University, CA, USA
    Clin Lung Cancer 13:52-8. 2012
    ..We evaluated the prognostic value of metabolic tumor volume (MTV), a measure of tumor burden on FDG-PET imaging, in patients with non-small-cell lung cancer (NSCLC) treated definitively.
  80. ncbi Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma
    Frank J P Hoebers
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Head Neck 30:1216-23. 2008
    ..The purpose of this study was to evaluate the prognostic value of tumor volume in head and neck squamous cell carcinoma treated with chemoradiation...
  81. ncbi Time-resolved optical mammography and its preliminary clinical results
    Y Ueda
    Central Research Laboratory, Hamamatsu Photonics K K, 5000, Hirakuchi, Hamakita Ku, Hamamatsu City, Shizuoka Pref, 434 8601, Japan
    Technol Cancer Res Treat 10:393-401. 2011
    ..In a comparative study with conventional modalities, the breast cancers were detected as regions of optically higher absorption. Moreover, the results suggest that optical mammography is useful in monitoring the effects of chemotherapy...
  82. ncbi Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer
    Jong Ryool Oh
    Department of Nuclear Medicine, Chonnam National University Medical School and Hospital, 42 Jebong no, Donggu, Gwangju 501 757, Republic of Korea
    Eur J Nucl Med Mol Imaging 39:925-35. 2012
    ....
  83. ncbi Metabolic tumor burden predicts for disease progression and death in lung cancer
    Percy Lee
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
    Int J Radiat Oncol Biol Phys 69:328-33. 2007
    ..However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose-positron ..
  84. ncbi Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma
    Hyung Jun Im
    Department of Nuclear Medicine, National Cancer Center, Goyang si, Gyeonggi Do, Korea
    Eur J Nucl Med Mol Imaging 39:39-49. 2012
    ..Furthermore, little is known of the early PET/CT responses after only one chemotherapy course...
  85. ncbi Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases
    Nicholas F Marko
    Department of Neurosurgery, The Cleveland Clinic, Cleveland, OH 44195, USA
    World Neurosurg 73:186-93; discussion e29. 2010
    ....
  86. ncbi Dosimetric impact of online correction via cone-beam CT-based image guidance for stereotactic lung radiotherapy
    Ana Paula Galerani
    Department of Radiation Oncology, Clinirad, Angelina Caron Hospital, Curitiba, Parana, Brazil
    Int J Radiat Oncol Biol Phys 78:1571-8. 2010
    ..To evaluate the dosimetric impact of online cone-beam computed tomography (CBCT) guided correction in lung stereotactic body radiation therapy (SBRT)...
  87. ncbi Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer
    Xue Meng
    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, China
    Int J Radiat Oncol Biol Phys 82:960-6. 2012
    ....
  88. ncbi Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology
    Mathieu Hatt
    INSERM, U650 LaTIM, CHU Morvan, 5 avenue Foch, 29609 Brest, France
    Eur J Nucl Med Mol Imaging 38:1191-202. 2011
    ..The objectives of this work were to investigate the prognostic value of these indices in oesophageal cancer patients undergoing combined chemoradiotherapy treatment and the impact of TV delineation strategies...
  89. pmc p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner
    Yoseph Addadi
    Department of Biological Regulation, The Weizmann Institute, Rehovot, Israel
    Cancer Res 70:9650-8. 2010
    ..Moreover, expression of mutant p53 by tumor stroma fibroblasts might exert a gain of function effect, further accelerating tumor development...
  90. ncbi Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer
    James Stewart
    Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto, Canada
    Int J Radiat Oncol Biol Phys 78:350-8. 2010
    ..In addition, the dosimetric consequences of organ and tumor motion are modeled using a combination of deformable registration and fractional dose accumulation techniques...
  91. pmc Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts
    Wei Meng Zhao
    Galaxy Biotech, LLC, Sunnyvale, California 94089, USA
    Clin Cancer Res 16:5750-8. 2010
    ..We investigated whether monoclonal antibodies (mAbs) directed against FGFR2 can inhibit the growth of tumors in xenograft models...
  92. ncbi Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma
    Peng Yuan Zhuang
    Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People s Republic of China
    J Cancer Res Clin Oncol 136:1891-900. 2010
    ..To elucidate the effect of IFN-α treatment on tumor growth and metastasis of hepatocellular carcinoma (HCC)...
  93. ncbi Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma
    Shahab Uddin
    Department of Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Endocr Relat Cancer 17:191-202. 2010
    ..Altogether, these data show that leptin plays an important role in PTC pathogenesis through PI3K/AKT pathway via Ob-R and is a potential prognostic marker associated with an aggressive phenotype and poor disease-free survival...
  94. pmc An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis
    Marion Zillhardt
    Department of Obstetrics, University of Chicago, Chicago, IL 60637, USA
    Neoplasia 12:1-10. 2010
    ..study was to determine whether blocking c-Met with an orally available c-Met inhibitor, PF-2341066, reduces tumor burden and increases survival in a xenograft model of ovarian cancer metastasis...
  95. ncbi Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
    ..of RANKL in models of breast cancer bone metastases blocks tumor-induced osteolysis and reduces skeletal tumor burden.  In addition, the skeleton is co-opted by tumor cells and functions as a supportive tumor microenvironment...
  96. ncbi Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells
    Ya Ling Weng
    Department of Food Science, National Chiayi University, Chaiyi, Taiwan
    Mol Nutr Food Res 54:259-67. 2010
    ..Tumor lumps or nodules were not detected at the injection sites or in the lungs. This reveals that intrinsic vaccination-like defense has resulted from administration of resveratrol and challenge of tumor cells...
  97. ncbi Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma
    Stephanie J Gros
    Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Mol Cancer Ther 9:2037-45. 2010
    ..Treatment of this highly treatment-resistant disease with trastuzumab in the adjuvant setting to prevent lymph node metastasis after primary tumor resection is suggested by the data in this report...
  98. ncbi SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo
    Shuang Zhang
    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, People s Republic of China
    Clin Cancer Res 17:4439-50. 2011
    ..However, currently most of these anticancer drugs suffer some adverse effects. Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed...
  99. ncbi Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET/CT
    Xingchen Wu
    Department of Oncology, Tampere University Hospital, Tampere, Finland
    Mol Imaging Biol 13:785-92. 2011
    ....
  100. pmc Partial volume correction strategies for quantitative FDG PET in oncology
    Nikie J Hoetjes
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:1679-87. 2010
    ..The purpose of the present study was to assess accuracy and precision of different partial volume correction (PVC) methods...
  101. ncbi A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy
    R Bryan Barriger
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 82:457-62. 2012
    ..To examine the rates and risk factors of radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT)...

Research Grants84

  1. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..combinations of encapsulated siRNAs and/or histone deacetylase inhibitors (HDACIs) more effectively reduce tumor burden, the time to onset, rate of occurrence and mortality compared to individual encapsulated siRNAs in a ..
  2. EPIMORPHIN DELETION ALTERS STEM CELL NICHE MYOFIBROBLAST SECRETION
    Anisa Shaker; Fiscal Year: 2012
    ..We have shown in a murine model of CAC that Epim-/- mice have markedly reduced dysplastic tumor burden. We have also demonstrated that epimorphin deletion increases secretion of Chordin from colonic myofibroblasts ..
  3. Combined use of green tea and quercetin in prostate cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2012
    ..This novel treatment will retain the non-toxic character of green tea and at the same time increase its activity in chemoprevention of CaP. ..
  4. ROCK inhibitor suppression of GVHD with retention of GVL response
    Sujatha Iyengar; Fiscal Year: 2012
    ..for each drug will be used to suppress GVHD in the presence of infused host- syngeneic leukemia cells, and tumor burden will be monitored in treated and untreated mice...
  5. Mechanism of p63-Dependent Tumor Suppression
    Xinbin Chen; Fiscal Year: 2012
    ..Likewise, mice heterozygous for p63 developed an increased tumor burden and metastasis rate, which was compounded in mice harboring heterozygous alleles of p53 and/or p73...
  6. Treatment of breast cancer tumor growth and metastasis with an anti-MMP-9 DNAzyme
    MIRANDA A HALLETT; Fiscal Year: 2011
    ..Thus, in this proposal we are taking an innovative approach to the treatment of breast carcinomas by studying the effect of the AM9D therapy on tumor growth and metastasis, the major mechanism of morbidity and mortality. ..
  7. The Role of Beta-Gal Mediated Interactions in Prostate Cancer Metastasis
    VLADISLAV V GLINSKII; Fiscal Year: 2013
    ..cancer chemotherapy could benefit greatly patients with advanced metastatic prostate disease by reducing tumor burden, enhancing quality of life, and reducing morbidity and mortality...
  8. Signaling of Integrin Alpha 7
    Jianhua Luo; Fiscal Year: 2009
    ..abstract_text> ..
  9. Signaling of Integrin Alpha 7
    Jianhua Luo; Fiscal Year: 2013
    ....
  10. Mesothelioma inhibition by secoisolariciresinol diglucoside (SDG)
    Melpo Christofidou-Solomidou; Fiscal Year: 2013
    ..If our intervention proves effective in inhibiting inflammation, delaying the onset of malignancy or decreasing tumor burden in any of the models, we will pursue mechanistic studies to evaluate SDG in asbestos-exposed mesothelial cells ..
  11. Systemic Chemotherapy of Melanoma: NMR Studies of Lonidamine &N-Mustard Activity
    Jerry D Glickson; Fiscal Year: 2013
    ..3) To evaluate potential 1H NMR markers for noninvasive early detection of response--lactate and total choline by MRS and apparent diffusion constant (ADC) and T2 measured by MRI. ..
  12. Targeted nanoparticle gene therapy for lung cancer
    Masaaki Tamura; Fiscal Year: 2013
    ..Observations of the treated lungs revealed a remarkable reduction in tumor burden, without any signs of toxicity toward the native tissue, nor signs of inflammation...
  13. Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma
    Paul Nghiem; Fiscal Year: 2013
    ..Moreover, anti-T-Ag antibody titers are dynamic in MCC patients and increase in parallel to tumor burden, allowing detection of disease progression in some cases before identification by the patient or physician...
  14. Biomarker Prediction of Gleason Upgrading
    Bruce J Trock; Fiscal Year: 2010
    ..If successful, this project may lead to methods that can increase the acceptability and safety of following patients with a program of AS, and reduce over treatment of prostate cancer. ..
  15. Quercetin to enhance the bioavailability and activity of green tea polyphenols
    SUSANNE MARGARETE HENNING; Fiscal Year: 2013
    ..The results will lay the foundation for future clinical trials to evaluate the interaction of quercetin and GT in chemoprevention of early stages of prostate cancer. ..
  16. Soy isoflavones to augment radiotherapy of lung carcinoma
    Gilda G Hillman; Fiscal Year: 2012
    ..The results of this investigation will have high impact on the management of patients diagnosed with lung cancer. ..
  17. A Novel IgE Cancer Therapeutic Specific for the Epithelial Membrane Protein-2
    TRACY RUTH DANIELS-WELLS; Fiscal Year: 2013
    ..Given the high expression of EMP2 on a number of malignancies, these studies will be important to establish the anti-EMP2 IgE as a potential therapeutic for cancers in women. ..
  18. Prevention of mammary tumors by metformin in comparison to calorie restriction
    Margot P Cleary; Fiscal Year: 2013
    ..Our hypothesis is that metformin will reduce mammary tumor incidence, extend latency and reduce tumor burden to a similar degree as moderate calorie restriction...
  19. Characterization of the Plasma Proteome in Mouse Models of Colon Cancer
    Kenneth E Hung; Fiscal Year: 2010
    ..The proposed plan extends the preliminary studies to determine if one can: 1) identify mice with minimal tumor burden, 2) discriminate between mice with tubular and villous adenomas, and 3) identify mice with carcinomas...
  20. Immune effector-mediated killing of CNS tumors in the GL261 model of glioblastoma
    DANIELLE RENNER; Fiscal Year: 2013
    ....
  21. Role of Reishi on cell surface proteins and signaling modulation in IBC
    IVETTE SUAREZ; Fiscal Year: 2013
    ....
  22. Mechanisms for the Transition to Castrate Resistant Prostate Cancer
    Stephen R Plymate; Fiscal Year: 2013
    ..This proposal should also shed significant new light on mechanisms of progression to the lethal form of prostate. ..
  23. The Role of Peroxiredoxin1 &Reactive Oxygen Species in Breast Tumor Initiation
    Carola Anke Neumann; Fiscal Year: 2013
    ..cells into clear fad pads of NCR nude mice, to observe if nuclear Prdx1 decreases incidence of breast cancer or tumor burden. Mice lacking Prdx1 offer the first mouse model where loss of a peroxidase results in elevation of endogenous ..
  24. Evaluating the role of Thrombospondin-1-CD47 mediated nitric oxide signaling in t
    Sarah Amend; Fiscal Year: 2013
    ..This leads to a "vicious cycle" of osteoclast activation and tumor cell proliferation, causing increased tumor burden and bone lesions...
  25. The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma
    MARCO L DAVILA; Fiscal Year: 2012
    ..to lymphomas due to a myc transgene, with anti-CD19 T cells to determine if there is an improvement in tumor burden and/or survival...
  26. The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens &Tumors
    Mary M Zutter; Fiscal Year: 2013
    ..In HPV16/2-null mice, tumor latency and tumor growth are not altered in mice lacking the 21 integrin, but tumor burden and the number of animals with lymph node metastasis is markedly decreased in 2-null mice compared to wild type ..
  27. Multiphoton Fluorescence Lifetime Imaging of Solid Tumors Invivo
    V Krishnan Ramanujan; Fiscal Year: 2010
    ..Three-dimensional quantification of tumor burden will be carried out...
  28. Intratumoral genetic therapy for lung cancer
    Steven M Dubinett; Fiscal Year: 2013
    ..Finally, the clinical activity as reflected in reduction in tumor burden will be assessed...
  29. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..all-out attack") approach to the use of "evolutionarily enlightened" drug combinations to stabilize the tumor burden. Our goal is to minimize the probability of emergence of multi drug resistant clones (MDR), which are the ..
  30. Adiponectin effects on leptin signaling in hepatocellular carcinoma
    Neeraj Kumar Saxena; Fiscal Year: 2011
    ..Obese patients exhibit a higher risk for larger tumor burden, increased metastasis and poor prognosis...
  31. Role of Claudin-1 in Colon Cancer
    Punita Dhawan; Fiscal Year: 2013
    ..We further demonstrate multi-fold increase in colonic tumor burden (tumor incidence and growth) and aggressiveness in the offspring generated through the cross between APCmin and ..
  32. Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
    Emmanuel O Akala; Fiscal Year: 2010
    ..Frantic efforts have been made over the years to identify factors affecting successful treatment of cancer: tumor burden, tumor-cell heterogeneity, drug resistance, dose intensity, and poor selectivity of the drug...
  33. A Narrowed Window for Targeting Metabolic Flexibility in Breast Cancer Prevention
    Pepper J Schedin; Fiscal Year: 2013
    ..The slower, less energetically efficient weight gain of obese rats predicts post-OVX tumor burden and multiplicity, and metformin therapy dramatically suppresses tumor progression after OVX...
  34. A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
    JOYCE MARIE contact SLINGERLAND; Fiscal Year: 2010
    ..This trial may form the basis for subsequent, larger clinical trials to enhance the efficacy of endocrine therapy for breast cancer. ..
  35. IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
    Don J Diamond; Fiscal Year: 2013
    ..The long-term objective is to develop shIDO-ST into a suitable, effective therapy for the treatment of patients with advanced inoperable PDAC. ..
  36. Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
    GARSON DAVID ROODMAN; Fiscal Year: 2013
    ..of function will be grown in an immunocompromised mouse model of osteolytic MBD to determine the effects on tumor burden and bone destruction...
  37. Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches
    HEIKE ELIZABETH DALDRUP-LINK; Fiscal Year: 2012
    ..following Alk5 blockade by monitoring histopathologic characteristics of mammary adenocarcinomas, as well as tumor burden, tumor latency (to endpoint), and frequency of pulmonary metastasis, and further demonstrate that MR imaging ..
  38. Pathway Specific Imaging in VHL Deficient Renal Cancer
    PANKAJ K SETH; Fiscal Year: 2013
    ..mouse model of renal cell carcinoma, and that this "pharmacodynamic" measurement will correlate with decreased tumor burden in this model...
  39. Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
    Ali Syed Arbab; Fiscal Year: 2013
    ..We expect the results of this experimental proposal will shade lights on the mechanisms of resistance to anti- angiogenic treatments and allow clinician to change the strategy of future treatment for GBM or other solid tumors. ..
  40. LPA receptor signaling in colonic epithelia
    CHANGHYON CHRIS YUN; Fiscal Year: 2013
    ..in vitro, but direct in vivo evidence came from our studies that the absence of LPA2R results in decreased tumor burden in rodent models of colon cancer...
  41. Pharmacological targeting of the Unfolded Protein Response as an antitumor strate
    Constantinos Koumenis; Fiscal Year: 2012
    ..UPR which alone, or in combination with existing antitumor agents and modalities will be effective in reducing tumor burden in preclinical and clinical malignancies...
  42. Surgery and the Mechanisms of Lymph Node Metastases in Cutaneous Melanoma
    Richard Essner; Fiscal Year: 2011
    ..changes with the primary site, 2) To determine if the alterations in SN morphology are reversible, and 3) To determine if the restoration of the morphology or phenotype of sentinel lymph nodes results in diminished regional tumor burden.
  43. Integrin Targeted Therapy for the Treatment of Ovarian Cancer
    FRANK CALZONE; Fiscal Year: 2013
    ..Especially in patients with minimal tumor burden after surgical debulking, regimens of IP chemotherapy are effective and lead to an increased progression-free ..
  44. Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
    Ulrich G Steidl; Fiscal Year: 2013
    ..use and optimization of polychemotherapy and the development of new agents that transiently reduce the tumor burden, relapse continues to be the most common cause of death in acute myeloid leukemia (AML)...
  45. CYP1B1: A Molecular Target for Chemoprevention of Lung Adenocarcinoma
    Margie L Clapper; Fiscal Year: 2013
    ..The effects of CYP1B1 inhibition on change in total tumor burden (tumor volume as determined by MRI) and tumor stage will be determined...
  46. LRH-1: Structure-based Approach to Drug Design for Gastrointestinal Tumors
    James Bayrer; Fiscal Year: 2013
    ..Reduction of LRH-1 has been shown to reduce tumor burden in mouse models of FAP, and mRNA silencing of LRH-1 reduces pancreatic cancer cell proliferation...
  47. Targeting multiple skin cancer pathways using citrus auraptene and ATRA
    J Michael Mathis; Fiscal Year: 2012
    ..The tumorigenic properties of the resulting pathway suppressed cells will be determined. ..
  48. Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine
    Hari K Koul; Fiscal Year: 2013
    ..Work proposed in this application, will contribute to development of a novel AR targeted therapy that may translate into an effective treatment regiment against prostate cancer and is therefore, highly relevant to Veteran health. ..
  49. Serum exosome diagnosis for glioma
    XANDRA OWENS BREAKEFIELD; Fiscal Year: 2010
    ..RNA;2) to determine whether the mutant/variant EGFRvIII mRNA in serum/plasma exosomes can serve as a marker of tumor burden and/or progression in glioma patients;and 3) to initiate a systematic assessment of other known genetic changes ..
  50. The Use of 68Ga-DOTATOC and 18F-FDG PET/CT Imaging in the Evaluation of Newly Dia
    RONALD CLARK WALKER; Fiscal Year: 2013
    ..Finally we will combine these imaging data with a serum proteomic analysis and other patient information to develop a new multivariate model for the diagnosis of lung cancer. ..
  51. Fluorophore-Conjugated Antibodies for Imaging and Resection of GI Tumors
    Meng Yang; Fiscal Year: 2013
    ..monoclonal antibodies against tumor antigen CA19-9 and CEA or a combination of both to evaluate tumor burden in vivo in an orthotopic metastatic nude mouse model of human pancreatic and colon cancer and to facilitate the ..
  52. Identifying brain mediators distinguishing eustress and distress impact on cancer
    Lei Cao; Fiscal Year: 2013
    ..In contrast, social isolation (SI) is linked to increased tumor burden. However, both EE and SI increase the classical stress hormones, glucocorticoids and catecholamines, and ss-..
  53. TAS::75 0849::TAS
    Wenlin Deng; Fiscal Year: 2011
    ..abstract_text> ..
  54. Mechanisms Promoting Angiogenesis in Glioblastoma
    Candece L Gladson; Fiscal Year: 2013
    ..RELEVANCE: These studies have the potential to provide a paradigm shift in the understanding of tumor-associated angiogenesis in general and will suggest novel regimens for improved anti-angiogenesis therapy in GBM. ..
  55. Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer
    KEISHA NICOLE HARDEMAN; Fiscal Year: 2013
    ..lapatinib resistant cells will be more sensitive to phenformin in vivo, and the use of phenformin will reduce tumor burden. Our approach includes an assessment of drug treatment perturbations at a cellular level, complemented with a ..
  56. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2010
    ..on the integrity of the spindle checkpoint, and (c) the mechanism by which ApcMin/+ mice shift in tumor burden from the small intestine to colon in the BubRl-deficient genetic background...
  57. Chemoprevention of Lung Cancer with Anti-tumor B
    Ming You; Fiscal Year: 2010
    ..Furthermore, the results from this proposal will also provide significant insights on the active inhibitory components and how they affect lung carcinogenesis process. ..
  58. Development of Spectroscopic Biomarkers of Bone Quality in Metastatic Disease
    Xiaohong Bi; Fiscal Year: 2013
    ..bone quality measurements will be correlated with bone structure (by X-ray imaging and Micro-CT analysis), tumor burden (assessed by bioluminescence imaging in vivo), bone turnover (by serum biomarkers) and bone cell activities (by ..
  59. Defining the effects of bortezomib on NK cell activation in cancer
    Anil Shanker; Fiscal Year: 2013
    ..imperative to investigate novel combinatorial therapeutic strategies and their mechanistic cross-talk to reduce tumor burden and potentiate anti-tumor immune effector functions by overriding tumor-induced immunosuppression...
  60. The Role of EGFR Negative Regulators in GI Neoplasia
    Robert J Coffey; Fiscal Year: 2013
    ..We predict there will be increased tumor burden in the colon and rectum. Aim 3...
  61. Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBM
    Brian W Pogue; Fiscal Year: 2013
    ..IGDD/IGLD and PKB models in vivo on treatment outcomes in orthotopic murine models of GBM in short-term (tumor burden) and long-term (survival) studies...
  62. Novel Inhibitors of Prostate Cancer Progression
    Ajit K Verma; Fiscal Year: 2013
    ..The proposed study will determine for the first time whether and how Plumbagin can prevent and treat hormone refractory PCa. ..
  63. DIET METHIONINE--S-ADO, POLYAMINES AND MAMMARY TUMORS
    ERVIN HAWRYLEWICZ; Fiscal Year: 1993
    ..over-all objective of this study is to determine the biologic mechanism(s) involved with the increased mammary tumor burden in rats fed an enriched casein diet supplemented with methionine...
  64. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  65. Gene Therapy for Retinoblastoma
    Richard Hurwitz; Fiscal Year: 2003
    ..The ultimate goal of this gene therapy is to salvage the affected eye by reducing the tumor burden sufficiently to allow for local control of the disease...
  66. Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa
    Jeffrey Martin; Fiscal Year: 2009
    ..inhibitor (NNRTI)-based HAART regimen (efavirenz plus zidovudine/lamivudine) in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa; (2) Evaluate which pre-HAART parameters are predictive of KS ..
  67. In Vivo Flow Cytometry to Measure Circulating Tumor Load
    David Benaron; Fiscal Year: 2004
    ..If successful, this may lead to improved staging, treatment monitoring, and possibly earlier diagnosis. ..
  68. LCDIO FOR LYMPH NODE MR IMAGING
    Ralph Weissleder; Fiscal Year: 2001
    ..For example, recent clinical trials demonstrate that minimal nodal tumor burden in non-enlarged nodes is indeed detectable by LCDIO enhanced MR imaging...
  69. Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
    Rajendra G Mehta; Fiscal Year: 2010
    ..that treatment of animals with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, reduces colon tumor burden. However, 1,25(OH)2D3 causes hypercalcemia. In view of this numerous analogs of vitamin D have been synthesized...
  70. SAMARIUM-145 SOURCES FOR BRACHYTHERAPY
    KRISHNAN SUTHANTHIRAN; Fiscal Year: 1991
    ..This project will investigate the feasibility of producing a high quality, leakage free, encapsulated source of Sm-145 and commercializing this new brachytherapy source...
  71. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2002
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  72. DIETARY SOYBEAN COMPONENTS AFFECT ON PROSTATE CANCER PRO
    Jin Rong Zhou; Fiscal Year: 2001
    ..It is expencted that the results from proposed project will be translated to future clinical trials on CaP prevention/intervention. ..
  73. GLOBE CONSERVATION IN TRANSGENIC RETINOBLASTOMA
    Timothy Murray; Fiscal Year: 2006
    ..Pilot data suggests that angiostatic therapy is effective in the reduction of tumor burden in a murine transgenic model of retinoblastoma...
  74. A Phase II Trial for Neutron Capture Therapy in Melanoma
    Paul Busse; Fiscal Year: 2003
    ..These data will be used to refine the predictive accuracy of a two-compartment pharmacokinetic model developed by this research group from human clinical data. ..
  75. PROGESTERONE RECEPTOR IN MYOMETRIUM AND LEIOMYOMA
    Robin Fuchs Young; Fiscal Year: 2002
    ..are often associated with infertility and an additional 18,000 myomectomies are performed each year to reduce tumor burden while sparing the uterus...
  76. Liposome Delivery of Boron for BNCT
    M Hawthorne; Fiscal Year: 2007
    ..The normal tissue response will be quantified in a rat model. The proposed studies will provide the radiobiological data required to decide whether to proceed to large animal or human studies. ..
  77. GLYCOPROTEIN SHEDDING AND METASTASIS
    BRUCE BOSMANN; Fiscal Year: 1980
    ..shedding: first, correlation of serum glycoprotein:N-acetylneuraminic acid transferase activity with tumor burden and second, identification, characterization and kinetics of release (shedding) of tumor glycoproteins...
  78. Predicting Non-Sentinel Node Metastasis in Breast Cancer Patients
    Anees Chagpar; Fiscal Year: 2009
    ..RT-PCR based assay (GeneSearch(r)) for detecting SLN micrometastases has been shown to correlate with SLN tumor burden in breast cancer patients...
  79. RAT MODEL OF TRANSPLANTABLE HEPATOCELLULAR CARCINOMA
    Douglas Hixson; Fiscal Year: 1992
    ..The specific aims of this proposal are: 1). To develop and optimize methods for the quantitation of tumor burden. Enzymatic and immunological assays for DPPIV will be used to provide a definitive measurement of tumor burden ..
  80. Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
    Xin Wang; Fiscal Year: 2009
    ..Finding mechanisms to relieve symptom burden and improve the function of the many patients undergoing curative aggressive cancer treatment such as chemoradiation has immense public health significance. ..
  81. HYPERTHERMIA AND BRACHYTHERAPY IN BRAIN TUMOR TREATMENT
    David Roberts; Fiscal Year: 1990
    ..The time/temperature escalation study will be performed using a 915 MHz spiral surface applicator in normal dog brain and the analysis will be based on histological and neuroradiological evaluation 7 days after treatment...
  82. The Role of Memory T-Cells in Pathogenesis
    JOSEPH KISSIL; Fiscal Year: 2009
    ..of lung adenocarcinoma, but that tumor-specific T cell responses will become progressively less functional as tumor burden increases...
  83. Liquid Cooling Cycle for Ablation Using Integrated Thermal and Imaging Feedback
    ALEXEI BABKIN; Fiscal Year: 2009
    ..The current proposal defines background research for potential major advances in cryotherapy treatments for cancer. ..
  84. Multiresolution-fractal modeling for brain tumor detection
    Khan M Iftekharuddin; Fiscal Year: 2010
    ..The results obtained from this project will have immediate impact in neuroradiology practice by providing an accurate, objective, and consistent way to evaluate and interpret brain tumors. ..